HKMPY (Hikma Pharmaceuticals) Cash Flow for Dividends: $-185 Mil (TTM As of Dec. 2025)


HKMPY Hikma Pharmaceuticals PLC HKMPY
87 GF Score
Price $41.23
GF Value $56.71
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Hikma Pharmaceuticals Cash Flow for Dividends?

Hikma Pharmaceuticals HKMPY 87 Cash Flow for Dividends is $-185 Mil as of Dec. 2025. GuruFocus rates HKMPY with a GF Score™ of 87/100 and a GF Value™ of $56.71 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Hikma Pharmaceuticals's cash flow for dividends for the six months ended in Dec. 2025 was $-79 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Dec. 2025 was $-185 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

Hikma Pharmaceuticals's quarterly payment of dividends increased from Dec. 2024 ($-71 Mil) to Jun. 2025 ($-106 Mil) but then declined from Jun. 2025 ($-106 Mil) to Dec. 2025 ($-79 Mil).

Hikma Pharmaceuticals's annual payment of dividends increased from Dec. 2023 ($-137 Mil) to Dec. 2024 ($-175 Mil) and increased from Dec. 2024 ($-175 Mil) to Dec. 2025 ($-185 Mil).

Hikma Pharmaceuticals Cash Flow for Dividends Related Terms

Hikma Pharmaceuticals Cash Flow for Dividends Historical Data

* Premium members only.

The historical data trend for Hikma Pharmaceuticals's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hikma Pharmaceuticals Cash Flow for Dividends Chart

Hikma Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash Flow for Dividends
Get a 7-Day Free Trial Premium Member Only Premium Member Only -120.00 -125.00 -137.00 -175.00 -185.00

Hikma Pharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Cash Flow for Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -55.00 -104.00 -71.00 -106.00 -79.00
HKMPY
87GF Score
Hikma Pharmaceuticals PLC HKMPY
Cash Flow for Dividends is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hikma Pharmaceuticals Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-185 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow for Dividends of $-185 Mil mean?
Hikma Pharmaceuticals (HKMPY) has a Cash Flow for Dividends of $-185 Mil as of Dec. 2025. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Hikma Pharmaceuticals and its competitors.
Is Hikma Pharmaceuticals' Cash Flow for Dividends too high?
Hikma Pharmaceuticals' current Cash Flow for Dividends is $-185 Mil. Overall, Hikma Pharmaceuticals has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hikma Pharmaceuticals' Cash Flow for Dividends compare to ZTS and UTHR?
Hikma Pharmaceuticals' Cash Flow for Dividends of $-185 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow for Dividends for a Drug Manufacturers company?
A good Cash Flow for Dividends depends on the Drug Manufacturers industry context. However, Cash Flow for Dividends should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow for Dividends mean?
A high Cash Flow for Dividends can signal that a stock is expensive relative to its fundamentals. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Hikma Pharmaceuticals and its competitors. Hikma Pharmaceuticals's current Cash Flow for Dividends is $-185 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hikma Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Hikma Pharmaceuticals (HKMPY) is currently considered Modestly Undervalued. The stock's GF Value™ is $56.71, compared to a current price of $41.23 — trading 27.3% below its estimated fair value. The current Cash Flow for Dividends is $-185 Mil. Hikma Pharmaceuticals' overall GF Score™ is 87/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow for Dividends calculated?
Cash Flow for Dividends is calculated from a company's financial statements. For Hikma Pharmaceuticals (HKMPY), the current Cash Flow for Dividends is $-185 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hikma Pharmaceuticals (HKMPY) Overvalued in 2026?

Based on GuruFocus' analysis, Hikma Pharmaceuticals stock appears to be undervalued. The current stock price of $41.23 is trading 27.3% below its estimated GF Value™ of $56.71. GuruFocus considers Hikma Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for HKMPY:

  • Cash Flow for Dividends: $-185 Mil
  • GF Value™: $56.71 vs. price of $41.23 (27.3% below fair value)
  • GF Score™: 87/100 with 5 warning signs

No single metric tells the full story. See the HKMPY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hikma Pharmaceuticals Business Description

Address 10 Portman Square, London, GBR, W1H 6AZ
Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, Rx, and branded. The majority of the company's revenue is generated from its injectables segment, which supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue-generating market, followed by the Middle East and North Africa, the United Kingdom, Europe, and the rest of the world.
87GF Score

Get the complete analysis for HKMPY

Cash Flow for Dividends is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$41.23
Price
$56.71
GF Value